Private Label Resurfacing Serum Manufacturer USA Low MOQ

Do private label resurfacing serums need to be FDA approved before selling?

By Blake Mereby · Last reviewed October 5, 2026

No, cosmetic resurfacing serums do not require FDA pre-market approval before they can be sold in the United States. The FDA regulates cosmetics under a post-market framework, meaning the responsibility for product safety rests with the manufacturer and the brand owner, not with a government review process before sale. However, this does not mean resurfacing serums are unregulated — there are meaningful compliance obligations that every brand must meet.

Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which took full effect in late 2023, cosmetic manufacturers and brand owners must: register their facilities with the FDA, list their products and ingredient statements, maintain safety substantiation records for each product, report serious adverse events to the FDA within 15 days, and comply with good manufacturing practice regulations once the FDA finalizes those rules (expected by late 2025).

The critical nuance for resurfacing serums is the cosmetic vs. drug distinction. If your product makes only cosmetic claims — "exfoliates," "smooths texture," "brightens skin" — it is a cosmetic and does not require pre-market approval. If your product makes drug claims — "treats acne," "reduces wrinkles" (in the specific FDA-defined sense), "treats keratosis pilaris" — it may be classified as an OTC drug, which does require compliance with FDA OTC monograph requirements or, if outside a monograph, a New Drug Application.

Salicylic acid-based resurfacing serums marketed with acne claims fall under the FDA's OTC acne drug monograph. This requires a Drug Facts panel, specific labeling language, and use of salicylic acid within the monograph's permitted concentration range (0.5–2%). Some brands choose to position BHA serums as cosmetics by limiting claims to exfoliation, avoiding the OTC drug pathway entirely.

At the state level, California's Proposition 65 may require warning labels if your formula contains ingredients at levels above established safe harbor thresholds. Retinyl palmitate and certain fragrance components are areas to evaluate with your cosmetic chemist.

Safety substantiation — the documented evidence that your product is safe as labeled — is required under MoCRA but is not submitted to the FDA; it is maintained in your own records and must be produced if the FDA requests it. This substantiation should include stability data, preservative efficacy results, and ideally a dermatologist or cosmetic toxicologist safety assessment.

When you post a project brief on AJ Cosmo Labs, you can specify that you need a manufacturer with MoCRA-compliant facility registration and the ability to provide full safety documentation, ensuring you only connect with partners who can support a legally compliant product launch.

Ingredients in this answer: Salicylic Acid · Retinyl Palmitate

Read the full guide on Private Label Resurfacing Serum Manufacturer USA Low MOQ →

More about Private Label Resurfacing Serum Manufacturer USA Low MOQ

Tell us about your product

Tell us what you're selling and where. You can hire a vetted cosmetic chemist on AJ Cosmo Labs to review your formula and labeling. Starting is free.

Free to start · no credit card · continue in your browser or the iPhone app.

Have a product idea?

Connect with vetted cosmetic chemists and custom labs on AJ Cosmo Labs.

Get on the App Store Open the web app